Karleen Oberton - Hologic CFO, Chief Accounting Officer

HOLX Stock  USD 75.10  0.18  0.24%   

CFO

Ms. Karleen Marie Oberton is Chief Financial Officer of the Company. She joined Hologic in 2006 as corporate controller and was promoted to Chief Accounting Officer in 2015. Before joining Hologic, Ms. Oberton served as senior corporate controller of Immunogen from 2004 to 2006. Prior to that, she was an Audit Senior Manager in Ernst Youngs Life Science practice and in Arthur Andersens High Technology practice since 2018.
Age 53
Tenure 6 years
Address 250 Campus Drive, Marlborough, MA, United States, 01752
Phone508 263 2900
Webhttps://www.hologic.com
Oberton was an active Certified Public Accountant for more than 18 years and holds a BS in Business Administration from Merrimack College. She is a member of Merrimack College’s Leadership Council.

Hologic Management Efficiency

The company has return on total asset (ROA) of 0.0649 % which means that it generated a profit of $0.0649 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1057 %, meaning that it created $0.1057 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Hologic's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.09 in 2024, whereas Return On Capital Employed is likely to drop 0.08 in 2024. At this time, Hologic's Asset Turnover is fairly stable compared to the past year.
The company currently holds 2.82 B in liabilities with Debt to Equity (D/E) ratio of 0.57, which is about average as compared to similar companies. Hologic has a current ratio of 3.82, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Hologic until it has trouble settling it off, either with new capital or with free cash flow. So, Hologic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hologic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hologic to invest in growth at high rates of return. When we think about Hologic's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 12 records

CFO Age

David MurrayAlcon AG
55
Bernard BirkettMerit Medical Systems
47
Gregory MatzThe Cooper Companies
56
Christopher LindopHaemonetics
56
William FedericiWest Pharmaceutical Services
57
Scott LambICU Medical
55
Michael TrimarchiAngioDynamics
34
Brett SandercockResMed Inc
57
MBA BSTeleflex Incorporated
62
Raul ParraMerit Medical Systems
39
Timothy StonesiferAlcon AG
57
James CPAHaemonetics
53
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for womens health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. Hologic operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 6705 people. Hologic (HOLX) is traded on NASDAQ Exchange in USA. It is located in 250 Campus Drive, Marlborough, MA, United States, 01752 and employs 6,990 people. Hologic is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Hologic Leadership Team

Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
Wayne Wilson, Independent Director
Namal Nawana, Director
Peter Dunne, Senior Resources
Sally Crawford, Independent Director
Erik Anderson, Division Solutions
Mark Irving, VP Secretary
Jay Stein, Co-Founder, Chairman Emeritus, Chief Technical Officer and Sr. VP
Stephen MacMillan, Chairman, CEO and Pres
Sanjay Prabhakaran, Regional President - Asia
Claus Egstrand, Senior Vice President General Manager - International
Ludwig Hantson, Director
Jennifer Schneiders, President Solutions
Samuel Merksamer, Independent Director
Christiana Stamoulis, Director and Member of Corporate Devel. Committee
Robert McMahon, CFO
Essex Mitchell, Chief Officer
Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
Karleen Oberton, CFO, Chief Accounting Officer
Monica Berthelot, VP Staff
Thomas West, Division President of Diagnostics Solutions
Eric Compton, COO
Paul Malenchini, Chief Officer
Lawrence Levy, Independent Director
Benjamin Cohn, Principal Chief Accounting Officer
Elaine Ullian, Independent Director
Kevin Thornal, Group Solutions
Amy Wendell, Director
Scott Garrett, Independent Director
Peter Valenti, Division President- Breast and Skeletal Health
Nancy Leaming, Independent Director
Scott Christensen, Quality Chain
Elisabeth Hellmann, Sr Communications
John Griffin, General Counsel
Allison Bebo, Senior Vice President - Human Resources
Mike Kelly, Chief Affairs
Charles Dockendorff, Director
Michael Watts, Vice President IR Contact Officer
Ryan Simon, Vice Relations
Jonathan Christodoro, Independent Director
Al Kildani, Senior Director - Investor Relations
Brandon Schnittker, Division Solutions

Hologic Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Hologic Investors Sentiment

The influence of Hologic's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Hologic. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Hologic's public news can be used to forecast risks associated with an investment in Hologic. The trend in average sentiment can be used to explain how an investor holding Hologic can time the market purely based on public headlines and social activities around Hologic. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Hologic's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Hologic's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Hologic's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Hologic.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hologic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hologic's short interest history, or implied volatility extrapolated from Hologic options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Hologic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hologic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hologic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hologic Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more information on how to buy Hologic Stock please use our How to Invest in Hologic guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Complementary Tools for Hologic Stock analysis

When running Hologic's price analysis, check to measure Hologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hologic is operating at the current time. Most of Hologic's value examination focuses on studying past and present price action to predict the probability of Hologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hologic's price. Additionally, you may evaluate how the addition of Hologic to your portfolios can decrease your overall portfolio volatility.
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Global Correlations
Find global opportunities by holding instruments from different markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Is Hologic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hologic. If investors know Hologic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hologic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.373
Earnings Share
2.11
Revenue Per Share
16.228
Quarterly Revenue Growth
(0.06)
Return On Assets
0.0649
The market value of Hologic is measured differently than its book value, which is the value of Hologic that is recorded on the company's balance sheet. Investors also form their own opinion of Hologic's value that differs from its market value or its book value, called intrinsic value, which is Hologic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hologic's market value can be influenced by many factors that don't directly affect Hologic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hologic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hologic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hologic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.